These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25185651)

  • 1. Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy.
    Liu XF; Zhang H; Sun JQ; Yin C; Liu TF; Yang H; Chen LH
    Tumour Biol; 2014 Dec; 35(12):12409-14. PubMed ID: 25185651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Lee SJ; Choi YL; Park YH; Kim ST; Cho EY; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):743-51. PubMed ID: 21170649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
    Lee S; Park YH; Kim KH; Cho EY; Ahn YC; Kim K; Shim YM; Ahn JS; Park K; Im YH
    Br J Cancer; 2010 Sep; 103(6):845-51. PubMed ID: 20700125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy.
    Yeh CN; Jung SM; Chen TW; Hwang TL; Jan YY; Chen MF
    Langenbecks Arch Surg; 2010 Mar; 395(3):217-25. PubMed ID: 20012317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
    Gao J; He Q; Hua D; Mao Y; Li Y; Shen L
    Clin Transl Oncol; 2013 Aug; 15(8):619-25. PubMed ID: 23263912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.
    Hua D; Huang ZH; Mao Y; Deng JZ
    World J Gastroenterol; 2007 Oct; 13(37):5030-4. PubMed ID: 17854149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness.
    Kuniyasu T; Nakamura T; Tabuchi Y; Kuroda Y
    Cancer; 1998 Oct; 83(7):1300-6. PubMed ID: 9762929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
    Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of thymidylate synthase in relation to survival and chemosensitivity in gastric cancer patients.
    Tsujitani S; Konishi I; Suzuki K; Oka S; Gomyo Y; Matsumoto S; Hirooka Y; Kaibara N
    J Exp Clin Cancer Res; 2000 Jun; 19(2):189-95. PubMed ID: 10965817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.
    Okines AFC; Norman AR; McCloud P; Kang YK; Cunningham D
    Ann Oncol; 2009 Sep; 20(9):1529-1534. PubMed ID: 19474114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
    He MM; Wu WJ; Wang F; Wang ZQ; Zhang DS; Luo HY; Qiu MZ; Wang FH; Ren C; Zeng ZL; Xu RH
    PLoS One; 2013; 8(12):e82798. PubMed ID: 24349363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
    Koopman M; Venderbosch S; van Tinteren H; Ligtenberg MJ; Nagtegaal I; Van Krieken JH; Punt CJ
    Eur J Cancer; 2009 Jul; 45(11):1999-2006. PubMed ID: 19457654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
    Hwang IG; Ji JH; Kang JH; Lee HR; Lee HY; Chi KC; Park SW; Lee SJ; Kim ST; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
    J Geriatr Oncol; 2017 May; 8(3):170-175. PubMed ID: 28119041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
    Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
    J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
    Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
    J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
    Garcia AA; Blessing JA; Darcy KM; Lenz HJ; Zhang W; Hannigan E; Moore DH
    Gynecol Oncol; 2007 Mar; 104(3):572-9. PubMed ID: 17049588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil.
    Tajima Y; Shimoda T; Nakanishi Y; Yokoyama N; Tanaka T; Shimizu K; Saito T; Kawamura M; Kusano M; Kumagai K
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):683-90. PubMed ID: 14576935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.